Oral Contraceptives Impact Quality of Life
By HospiMedica International staff writers Posted on 03 May 2017 |
A new study demonstrates a statistically significant reduction in general wellbeing of women using oral contraceptives.
Researchers at Karolinska Institutet, Karolinska University Hospital, and other institutions conducted a double-blind, placebo-controlled trial involving 340 healthy women (18-35 years of age) who were randomized to a combined oral contraceptive (150 μg levonorgestrel and 30 μg ethinylestradiol) or placebo for three months of treatment. Primary outcome measures included global score of the Psychological General Well-Being Index (PGWBI) and the Beck Depression Inventory (BDI).
In all, 332 women completed data collection at follow-up evaluation. The results showed that the oral contraceptive treatment significantly decreased general wellbeing, compared with placebo. In addition, several PGWBI dimensions were decreased compared with placebo, including positive wellbeing, self-control, and vitality. The effect of oral contraceptives on depressive symptoms and on the PGWBI “depressed mood” dimension were not statistically significant. The study was published on April 19, 2017, in Fertility and Sterility.
“Despite the fact that an estimated 100 million women around the world use contraceptive pills, we know surprisingly little today about the pill’s effect on women’s health,” said lead author Professor Angelica Lindén Hirschberg, MD, of Karolinska Institutet. “The scientific base is very limited as regards the contraceptive pill’s effect on quality of life and depression, and there is a great need for randomized studies where it is compared with placebos.”
The combined oral contraceptive pill, colloquially known as "the pill", is a birth control method that includes a combination of an estrogen and a progestogen. When taken per-os daily, these pills inhibit female fertility (with reversibility). Pills containing ethinylestradiol and levonorgestrel are the first choice of combined oral contraceptives in Sweden and many other countries, as they are considered to entail the least risk of thrombosis among all combined contraceptive pills.
Researchers at Karolinska Institutet, Karolinska University Hospital, and other institutions conducted a double-blind, placebo-controlled trial involving 340 healthy women (18-35 years of age) who were randomized to a combined oral contraceptive (150 μg levonorgestrel and 30 μg ethinylestradiol) or placebo for three months of treatment. Primary outcome measures included global score of the Psychological General Well-Being Index (PGWBI) and the Beck Depression Inventory (BDI).
In all, 332 women completed data collection at follow-up evaluation. The results showed that the oral contraceptive treatment significantly decreased general wellbeing, compared with placebo. In addition, several PGWBI dimensions were decreased compared with placebo, including positive wellbeing, self-control, and vitality. The effect of oral contraceptives on depressive symptoms and on the PGWBI “depressed mood” dimension were not statistically significant. The study was published on April 19, 2017, in Fertility and Sterility.
“Despite the fact that an estimated 100 million women around the world use contraceptive pills, we know surprisingly little today about the pill’s effect on women’s health,” said lead author Professor Angelica Lindén Hirschberg, MD, of Karolinska Institutet. “The scientific base is very limited as regards the contraceptive pill’s effect on quality of life and depression, and there is a great need for randomized studies where it is compared with placebos.”
The combined oral contraceptive pill, colloquially known as "the pill", is a birth control method that includes a combination of an estrogen and a progestogen. When taken per-os daily, these pills inhibit female fertility (with reversibility). Pills containing ethinylestradiol and levonorgestrel are the first choice of combined oral contraceptives in Sweden and many other countries, as they are considered to entail the least risk of thrombosis among all combined contraceptive pills.
Latest Patient Care News
- First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
- Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization
- Game-Changing Innovation in Surgical Instrument Sterilization Significantly Improves OR Throughput
- Next Gen ICU Bed to Help Address Complex Critical Care Needs
- Groundbreaking AI-Powered UV-C Disinfection Technology Redefines Infection Control Landscape
- Clean Hospitals Can Reduce Antibiotic Resistance, Save Lives
- Smart Hospital Beds Improve Accuracy of Medical Diagnosis
- New Fast Endoscope Drying System Improves Productivity and Traceability
- World’s First Automated Endoscope Cleaner Fights Antimicrobial Resistance
- Portable High-Capacity Digital Stretcher Scales Provide Precision Weighing for Patients in ER
- Portable Clinical Scale with Remote Indicator Allows for Flexible Patient Weighing Use
- Innovative and Highly Customizable Medical Carts Offer Unlimited Configuration Possibilities
- Biomolecular Wound Healing Film Adheres to Sensitive Tissue and Releases Active Ingredients
- Wearable Health Tech Could Measure Gases Released From Skin to Monitor Metabolic Diseases
- Wearable Cardioverter Defibrillator System Protects Patients at Risk of Sudden Cardiac Arrest
- World's First AI-Ready Infrasound Stethoscope Listens to Bodily Sounds Not Audible to Human Ear